ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) Free cash flow 2016–2024
ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$74.1MFY2024 · since FY2016: -$59.7M → -$74.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$74.1M | +49.1% |
| FY2023 | -$145.6M | +15.0% |
| FY2022 | -$171.3M | -8047.3% |
| FY2021 | $2.2M | +103.9% |
| FY2020 | -$55.9M | +51.0% |
| FY2019 | -$114.1M | -5.4% |
| FY2018 | -$108.3M | -37.2% |
| FY2017 | -$79.0M | -32.3% |
| FY2016 | -$59.7M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ADAPY financial trends
ADAPY RevenueADAPY Net incomeADAPY Net marginADAPY Gross profitADAPY Gross marginADAPY Operating incomeADAPY Operating marginADAPY Operating cash flowADAPY Capital expendituresADAPY Return on equityADAPY Stock buybacksADAPY Dividends paidADAPY Total assetsADAPY Total liabilitiesADAPY Shareholders’ equityADAPY overview →